BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 27355476)

  • 1. Development of Patient Derived Xenograft Models of Overt Spontaneous Breast Cancer Metastasis: A Cautionary Note.
    Paez-Ribes M; Man S; Xu P; Kerbel RS
    PLoS One; 2016; 11(6):e0158034. PubMed ID: 27355476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis.
    Kerbel RS; Guerin E; Francia G; Xu P; Lee CR; Ebos JM; Man S
    Breast; 2013 Aug; 22 Suppl 2():S57-65. PubMed ID: 24074794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing.
    Man S; Munoz R; Kerbel RS
    Cancer Metastasis Rev; 2007 Dec; 26(3-4):737-47. PubMed ID: 17846863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer.
    Powell E; Shao J; Yuan Y; Chen HC; Cai S; Echeverria GV; Mistry N; Decker KF; Schlosberg C; Do KA; Edwards JR; Liang H; Piwnica-Worms D; Piwnica-Worms H
    Breast Cancer Res; 2016 Jan; 18(1):13. PubMed ID: 26818199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
    Kerbel RS
    Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterizing the efficacy of cancer therapeutics in patient-derived xenograft models of metastatic breast cancer.
    Turner TH; Alzubi MA; Sohal SS; Olex AL; Dozmorov MG; Harrell JC
    Breast Cancer Res Treat; 2018 Jul; 170(2):221-234. PubMed ID: 29532339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigating circulating tumor cells and distant metastases in patient-derived orthotopic xenograft models of triple-negative breast cancer.
    Ramani VC; Lemaire CA; Triboulet M; Casey KM; Heirich K; Renier C; Vilches-Moure JG; Gupta R; Razmara AM; Zhang H; Sledge GW; Sollier E; Jeffrey SS
    Breast Cancer Res; 2019 Aug; 21(1):98. PubMed ID: 31462307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models.
    Rosato RR; Dávila-González D; Choi DS; Qian W; Chen W; Kozielski AJ; Wong H; Dave B; Chang JC
    Breast Cancer Res; 2018 Sep; 20(1):108. PubMed ID: 30185216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors.
    Wang D; Pham NA; Tong J; Sakashita S; Allo G; Kim L; Yanagawa N; Raghavan V; Wei Y; To C; Trinh QM; Starmans MH; Chan-Seng-Yue MA; Chadwick D; Li L; Zhu CQ; Liu N; Li M; Lee S; Ignatchenko V; Strumpf D; Taylor P; Moghal N; Liu G; Boutros PC; Kislinger T; Pintilie M; Jurisica I; Shepherd FA; McPherson JD; Muthuswamy L; Moran MF; Tsao MS
    Int J Cancer; 2017 Feb; 140(3):662-673. PubMed ID: 27750381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Tumor Recurrence After Resection of Highly- and Poorly-Metastatic Triple-negative Breast Cancer in Orthotopic Nude-Mouse Models.
    Yano S; Takehara K; Kishimoto H; Tazawa H; Urata Y; Kagawa S; Fujiwara T; Bouvet M; Hoffman RM
    Anticancer Res; 2017 Jan; 37(1):57-60. PubMed ID: 28011473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
    Kerbel RS; Shaked Y
    Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of clinically relevant in vivo metastasis models using human bone discs and breast cancer patient-derived xenografts.
    Lefley D; Howard F; Arshad F; Bradbury S; Brown H; Tulotta C; Eyre R; Alférez D; Wilkinson JM; Holen I; Clarke RB; Ottewell P
    Breast Cancer Res; 2019 Nov; 21(1):130. PubMed ID: 31783893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vivo Selection of Intermediately- and Highly-Malignant Variants of Triple-negative Breast Cancer in Orthotopic Nude Mouse Models.
    Yano S; Takehara K; Kishimoto H; Tazawa H; Urata Y; Kagawa S; Bouvet M; Fujiwara T; Hoffman RM
    Anticancer Res; 2016 Dec; 36(12):6273-6277. PubMed ID: 27919946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spatiotemporal assessment of spontaneous metastasis formation using multimodal in vivo imaging in HER2+ and triple negative metastatic breast cancer xenograft models in mice.
    Fricke IB; De Souza R; Costa Ayub L; Francia G; Kerbel R; Jaffray DA; Zheng J
    PLoS One; 2018; 13(5):e0196892. PubMed ID: 29723251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.
    Navone NM; van Weerden WM; Vessella RL; Williams ED; Wang Y; Isaacs JT; Nguyen HM; Culig Z; van der Pluijm G; Rentsch CA; Marques RB; de Ridder CMA; Bubendorf L; Thalmann GN; Brennen WN; Santer FR; Moser PL; Shepherd P; Efstathiou E; Xue H; Lin D; Buijs J; Bosse T; Collins A; Maitland N; Buzza M; Kouspou M; Achtman A; Taylor RA; Risbridger G; Corey E
    Prostate; 2018 Dec; 78(16):1262-1282. PubMed ID: 30073676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-derived xenograft models of breast cancer and their predictive power.
    Whittle JR; Lewis MT; Lindeman GJ; Visvader JE
    Breast Cancer Res; 2015 Feb; 17(1):17. PubMed ID: 25849559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Labeling of Breast Cancer Patient-derived Xenografts with Traceable Reporters for Tumor Growth and Metastasis Studies.
    Hanna C; Kwok L; Finlay-Schultz J; Sartorius CA; Cittelly DM
    J Vis Exp; 2016 Nov; (117):. PubMed ID: 27929464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-derived xenografts of central nervous system metastasis reveal expansion of aggressive minor clones.
    Tew BY; Legendre C; Schroeder MA; Triche T; Gooden GC; Huang Y; Butry L; Ma DJ; Johnson K; Martinez RA; Pierobon M; Petricoin EF; O'shaughnessy J; Osborne C; Tapia C; Buckley DN; Glen J; Bernstein M; Sarkaria JN; Toms SA; Salhia B
    Neuro Oncol; 2020 Jan; 22(1):70-83. PubMed ID: 31433055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying biomarkers of breast cancer micrometastatic disease in bone marrow using a patient-derived xenograft mouse model.
    Pillai SG; Li S; Siddappa CM; Ellis MJ; Watson MA; Aft R
    Breast Cancer Res; 2018 Jan; 20(1):2. PubMed ID: 29291741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-targeting adenovirus OBP-401 inhibits primary and metastatic tumor growth of triple-negative breast cancer in orthotopic nude-mouse models.
    Yano S; Takehara K; Kishimoto H; Tazawa H; Urata Y; Kagawa S; Bouvet M; Fujiwara T; Hoffman RM
    Oncotarget; 2016 Dec; 7(51):85273-85282. PubMed ID: 27863373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.